Template:Estrogen dosages for menopausal hormone therapy
From HandWiki
Route/form | Estrogen | Low | Standard | High | |||
---|---|---|---|---|---|---|---|
Oral | Estradiol | 0.5–1 mg/day | 1–2 mg/day | 2–4 mg/day | |||
Estradiol valerate | 0.5–1 mg/day | 1–2 mg/day | 2–4 mg/day | ||||
Estradiol acetate | 0.45–0.9 mg/day | 0.9–1.8 mg/day | 1.8–3.6 mg/day | ||||
Conjugated estrogens | 0.3–0.45 mg/day | 0.625 mg/day | 0.9–1.25 mg/day | ||||
Esterified estrogens | 0.3–0.45 mg/day | 0.625 mg/day | 0.9–1.25 mg/day | ||||
Estropipate | 0.75 mg/day | 1.5 mg/day | 3 mg/day | ||||
Estriol | 1–2 mg/day | 2–4 mg/day | 4–8 mg/day | ||||
Ethinylestradiola | 2.5 μg/day | 5–15 μg/day | – | ||||
Nasal spray | Estradiol | 150 μg/day | 300 μg/day | 600 μg/day | |||
Transdermal patch | Estradiol | 25 μg/dayb | 50 μg/dayb | 100 μg/dayb | |||
Transdermal gel | Estradiol | 0.5 mg/day | 1–1.5 mg/day | 2–3 mg/day | |||
Vaginal | Estradiol | 25 μg/day | – | – | |||
Estriol | 30 μg/day | 0.5 mg 2x/week | 0.5 mg/day | ||||
IM or SC injection | Estradiol valerate | – | – | 4 mg 1x/4 weeks | |||
Estradiol cypionate | 1 mg 1x/3–4 weeks | 3 mg 1x/3–4 weeks | 5 mg 1x/3–4 weeks | ||||
Estradiol benzoate | 0.5 mg 1x/week | 1 mg 1x/week | 1.5 mg 1x/week | ||||
SC implant | Estradiol | 25 mg 1x/6 months | 50 mg 1x/6 months | 100 mg 1x/6 months | |||
Footnotes: a = No longer used or recommended, due to health concerns. b = As a single patch applied once or twice per week (worn for 3–4 days or 7 days), depending on the formulation. Note: Dosages are not necessarily equivalent. Sources: [1][2][3][4][5][6][7][8][9][10][11][12][13] |

See also
- Template:Estrogen dosages for breast and prostate cancer
- Template:Medications and dosages used in hormone therapy for transgender women
References
- ↑ "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric 8 Suppl 1: 3–63. 2005. doi:10.1080/13697130500148875. PMID 16112947. http://hormonebalance.org/images/documents/Kuhl%2005%20%20Pharm%20Estro%20Progest%20Climacteric_1313155660.pdf.
- ↑ Kuhl, Herbert; Wiegratz, Inka (1 January 2008) (in German). Klimakterium, Postmenopause und Hormonsubstitution (4 ed.). UNI-MED-Verlag. p. 188. ISBN 978-3-83742-043-2. https://www.amazon.de/Klimakterium-Postmenopause-Hormonsubstitution-Herbert-Kuhl/dp/3837420434/.
- ↑ Wiegratz, I.; Kuhl, H. (2007). "Praxis der Hormontherapie in der Peri- und Postmenopause". Gynäkologische Endokrinologie 5 (3): 141–149. doi:10.1007/s10304-007-0194-9. ISSN 1610-2894.
- ↑ "Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause". Climacteric 11 (2): 108–23. April 2008. doi:10.1080/13697130801983921. PMID 18365854.
- ↑ Laura Marie Borgelt (2010). Women's Health Across the Lifespan: A Pharmacotherapeutic Approach. ASHP. pp. 257–. ISBN 978-1-58528-194-7. https://books.google.com/books?id=riP3pxq2jWAC&pg=PA257.
- ↑ Pharmacotherapy: A Pathophysiologic Approach, Tenth Edition. McGraw-Hill Education. 23 January 2017. p. 1295. ISBN 978-1-259-58749-8. https://books.google.com/books?id=BwF9DQAAQBAJ.
- ↑ "Menopausal hormone therapy for vasomotor symptoms: balancing the risks and benefits with ultra-low doses of estrogen". Expert Opin Investig Drugs 16 (12): 2005–20. December 2007. doi:10.1517/13543784.16.12.2005. PMID 18042008.
- ↑ Marc A. Fritz; Leon Speroff (28 March 2012). Clinical Gynecologic Endocrinology and Infertility. Lippincott Williams & Wilkins. pp. 751–753. ISBN 978-1-4511-4847-3. https://books.google.com/books?id=KZLubBxJEwEC&pg=PA751.
- ↑ Thomas, John A.; Keenan, Edward J. (6 December 1986). "Estrogens and Antiestrogenic Drugs". Principles of Endocrine Pharmacology. Springer Science & Business Media. pp. 135–165. doi:10.1007/978-1-4684-5036-1_7. ISBN 978-1-4684-5036-1. https://books.google.com/books?id=mTagBQAAQBAJ&pg=PA150.
- ↑ Ruggiero, R (2002). "Estrogen: physiology, pharmacology, and formulations for replacement therapy". Journal of Midwifery & Women's Health 47 (3): 130–138. doi:10.1016/S1526-9523(02)00233-7. ISSN 15269523.
- ↑ [1]
- ↑ Laurence Brunton; John Lazo; Keith Parker (13 September 2005). Goodman & Gilman's The Pharmacological Basis of Therapeutics, Eleventh Edition. McGraw Hill Professional. p. 1553. ISBN 978-0-07-160891-6. https://books.google.com/books?id=PtWdBgnQdjMC. "These preparations differ widely in their oral potencies; e.g., a dose of 0.625 mg of conjugated estrogens generally is considered equivalent to 5 to 10 μg of ethinyl estradiol."
- ↑ Kutlesic, Ranko; Popovic, Jasmina; Stefanovic, Milan; Vukomanovic, Predrag; Andric, Aleksandra; Milosevic, Jelena (2016). "Menopausal hormone therapy: Benefits and different forms". Medicinski pregled 69 (7-8): 247–254. doi:10.2298/MPNS1608247K. ISSN 0025-8105. PMID 29693907.